Serotonin synthesis accelerating composition and oral composition for mental health
A chamomile extract with 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid enhances serotonin synthesis, addressing mental health issues by increasing TPH2 gene expression and improving symptoms such as stress and depression.
Patent Information
- Application Number
- JP2025030048
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-27
- Filing Date
- 2025-02-27
- Publication Date
- 2025-09-08
AI Technical Summary
There is a need for new ingredients that effectively promote serotonin synthesis to address mental health issues such as stress, depression, and insomnia, as existing supplements have limitations.
A composition containing a chamomile extract with 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid (GMC) is developed, which enhances serotonin synthesis by promoting the expression of genes related to serotonin production, and can be used in oral compositions for mental health.
The chamomile extract composition effectively promotes serotonin synthesis, helping to prevent and improve mental health disorders by increasing the expression of the TPH2 gene, thereby alleviating symptoms like stress, depression, and insomnia.
Smart Images

Figure 2025130726000001_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to a composition for promoting serotonin synthesis and an oral composition for mental health, as well as a chamomile extract suitable for these compositions. [Background technology]
[0002] In today's stressful society, people are exposed to various stressors such as changes in their living and working environments, complex interpersonal relationships, and physical and mental fatigue, and mental health problems caused by stress are becoming a major social problem.
[0003] To care for such mental health, for example, health supplements with excellent stress-reducing effects that contain spore-forming lactic acid bacteria in addition to one or more of ginseng, GABA-containing materials, imidazole dipeptide-containing materials, and black ginger extract (Patent Document 1), and anti-stress agents with oligosaccharides as active ingredients (Patent Document 2) have been reported.
[0004] On the other hand, serotonin is a neurotransmitter in the brain that balances the autonomic nervous system and relieves tension. A serotonin deficiency can lead to irritability, loss of ambition, loss of motivation at work, depression, and insomnia, affecting mental health.
[0005] As described above, a deficiency of serotonin can cause various diseases, and therefore research into components related to the secretion of serotonin is ongoing. For example, lactoferrin (Patent Document 3), lactic acid bacteria belonging to the genus Lactobacillus other than those belonging to the Lactobacillus delbrueckii group, and lactic acid bacteria belonging to the genus Pediococcus, or processed products thereof (Patent Document 4), have been reported to have the effect of promoting the synthesis of serotonin. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Japanese Patent Publication No. 2020-191853 [Patent Document 2] Japanese Patent Application Publication No. 2023-167322 [Patent Document 3] Japanese Patent Application Publication No. 2019-156814 [Patent Document 4] Japanese Patent Application Laid-Open No. 2017-061567 Summary of the Invention [Problem to be solved by the invention]
[0007] As mentioned above, various ingredients have been reported for mental health care such as stress relief. As such, the demand for mental health care is increasing, and there is a need to develop new ingredients that are effective for mental health care.
[0008] Under these circumstances, an object of the present invention is to provide a composition for promoting serotonin synthesis and an oral composition for mental health. [Means for solving the problem]
[0009] The present inventors have conducted extensive research to solve the above problems, and as a result have found that the following invention meets the above object, thereby completing the present invention.
[0010] That is, the present invention relates to the following inventions. <1> A composition for promoting serotonin synthesis, comprising a chamomile extract containing 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid. <2> The chamomile extract is extracted with one or more solvents selected from water, methanol, and ethanol. <1> The composition for promoting serotonin synthesis described in <3> A composition for promoting serotonin synthesis, comprising 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid as an active ingredient.
[0011] <4> <1> from <3> 10. An oral composition for mental health, comprising the composition for promoting serotonin synthesis according to any one of the preceding claims. <5> An oral composition for mental health containing a chamomile extract containing 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid. <6> It is a functional food or supplement <4> or <5> The oral composition according to claim 1.
[0012] <1a> A powder composition comprising a chamomile extract containing 20 mg / g or more of 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid and an excipient. <2a> The powder composition according to <1a>, wherein the excipient is dextrin.
[0013] <1b> Chamomile extract containing 30 mg / g or more of 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid. <2b> The chamomile extract according to <1b>, which is a dried product derived from a solvent extract. [Effects of the Invention]
[0014] According to the present invention, a composition for promoting serotonin synthesis and an oral composition for mental health are provided. [Brief explanation of the drawings]
[0015] [Figure 1] 1 is a graph showing the results of an evaluation test of serotonin synthesis in chamomile extract. [Figure 2] 1 is a graph showing the results of an evaluation test of serotonin synthesis with 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid (cis isomer, trans isomer). [Figure 3] 1 is a graph showing monthly changes in TMD (total mood state) in the example (chamomile group). [Figure 4] 1 is a graph showing monthly changes in VA (vigor and vitality) in the example (chamomile group). DETAILED DESCRIPTION OF THE INVENTION
[0016] The present invention will be described in detail below with reference to examples, but the present invention is not limited to the examples below and can be practiced with any modifications within the scope of the gist of the present invention. In this specification, the symbol "to" is used as an expression including the numerical value or physical quantity before and after it.
[0017] <1. Composition for promoting serotonin synthesis> The present invention relates to a composition for promoting serotonin synthesis, which contains a chamomile extract containing 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid (hereinafter, sometimes referred to as the "composition for promoting serotonin synthesis of the present invention").
[0018] The chamomile extract of the present invention promotes the synthesis of serotonin by promoting the expression of genes related to serotonin synthesis, and therefore can be used as an active ingredient in a composition for promoting serotonin synthesis.
[0019] The chamomile extract according to the present invention contains 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid (hereinafter, sometimes referred to as "GMC"). As shown in the examples (reference examples) described later, GMC has an excellent effect on promoting serotonin synthesis. Therefore, a composition for promoting serotonin synthesis containing GMC as an active ingredient can be prepared. Details of GMC will be described later.
[0020] The serotonin synthesis promoting effect of chamomile extract can be determined by evaluating the expression of the TPH2 gene, a serotonin synthase, and specifically, can be evaluated by the evaluation method "2-1. Evaluation of serotonin synthesis promoting effect" described in the Examples below.
[0021] The composition for promoting serotonin synthesis of the present invention contains GMC, which is an ingredient that exerts a serotonin synthesis promoting effect, but other ingredients that have a serotonin synthesis promoting effect can also be used in combination.
[0022] The composition for promoting serotonin synthesis of the present invention can prevent and improve various mental health disorders based on the serotonin synthesis promoting effect of chamomile extract.
[0023] The composition for promoting serotonin synthesis of the present invention can be used for oral or parenteral administration. When used for oral administration, the composition for promoting serotonin synthesis of the present invention can be suitably used as an "oral composition for mental health." Details of the oral composition for mental health will be described later. Furthermore, when the composition for promoting serotonin synthesis of the present invention is used orally, it can be used in the same manner as the "oral composition for mental health of the present invention" described below (functional foods, supplements, etc.).
[0024] The chamomile extract, which is the active ingredient of the composition for promoting serotonin synthesis of the present invention, will be described in detail below.
[0025] (chamomile extract) Chamomile, which is used as the raw material for chamomile extract (sometimes referred to as "raw chamomile"), is a dicotyledonous plant of the Asteraceae family, and is distributed from Europe to Western Asia. The type of raw material chamomile is not particularly limited as long as the desired chamomile extract can be obtained, and examples include German chamomile, Roman chamomile, wild chamomile, Moroccan chamomile, Cape chamomile, etc. These may be used alone or in combination of two or more.
[0026] Furthermore, the raw material chamomile can be used as a raw material at any time during the cultivation period as long as the effects of the present invention are not impaired. Chamomile may be a natural product or may be artificially cultivated.
[0027] As for the part of the raw material chamomile to be used, the whole plant may be used, or specific parts such as flowers, leaves, branches, roots, stems, rhizomes, seeds, buds, etc. may be used, as long as the effects of the present invention are not impaired. From the viewpoint of availability, above-ground parts (flowers, leaves, stems) are preferred, and flowers are particularly preferred. In this specification, the term "flower" refers to the parts of the flower distal to the rachis (petals, florets, flower buds, flower receptacles, pedicels, calyx, stamens, pistils, etc.). In other words, when using flowers as the raw material chamomile, parts of the flower, such as the petals alone, can be used alone, or two or more parts can be used in combination.
[0028] Although raw chamomile can be used for solvent extraction without any pretreatment, it is usually prepared into fine granules by slicing, crushing, squeezing, grating, etc. to improve extraction efficiency. Alternatively, dried shredded chamomile may be used.
[0029] In the present invention, the term "extract" is a general concept that refers to a form in which the content of active ingredients is increased by compressing or solvent extraction of the target raw plant material, or a product obtained by drying or shredding the plant material as necessary.
[0030] In the present invention, chamomile extract includes an extract obtained by extracting raw chamomile (including dried chamomile), a diluted or concentrated solution of the extract, or a crude or purified product thereof. Note that a dried product obtained by drying the extract is also considered to be an extract.
[0031] In the present invention, the chamomile extract also includes fractions. In this case, the fractions need only contain GMC, and may further contain other components. The fractionation method is not particularly limited as long as it can separate GMC, and for example, various types of chromatography can be used.
[0032] When a chamomile extract is obtained by solvent extraction, the extraction solvent may be any solvent that can extract the components contained in chamomile that exhibit the effect of promoting serotonin synthesis. Specific examples include water, methanol, ethanol, isopropyl alcohol, acetone, glycerin, ethylene glycol, butylene glycol, propylene glycol, dichloromethane, dichloroethane, chloroform, hexane, ethyl acetate, etc. These extraction solvents can be used alone or as a mixture of two or more of them, and when a mixture of two or more solvents is used as the extraction solvent, the mixing ratio can be appropriately adjusted as long as it does not impair the effects of the present invention.
[0033] The extraction solvent may contain additives, such as pH adjusters and viscosity adjusters, as long as the additives do not impair the effects of the present invention.
[0034] From the viewpoints of extraction efficiency and production costs, a suitable example of a chamomile extract is a solvent extract using one or more extraction solvents selected from water, methanol, and ethanol. A chamomile extract containing GMC can be obtained by using one or more extraction solvents selected from water, methanol, and ethanol.
[0035] When the preparation is to be used orally, it is preferable to use water, ethanol or a mixture thereof as the extraction solvent from the viewpoint of safety to the living body.
[0036] When water is used as the extraction solvent, the water used for extraction can be distilled water, pure water, or sterilized water. For example, tap water or water containing impurities may be used, but water that does not contain components that interfere with extraction from chamomile is preferred. As long as the effects of the present invention are not impaired, cold water, room temperature water, warm water, hot water, etc. can be used as the extraction solvent. However, warm water (35°C or higher) or hot water (70°C or higher) is preferred from the viewpoint of efficient extraction of chamomile-containing components.
[0037] When a mixed solvent of water and methanol is used as the extraction solvent, the mixing ratio of water and methanol may be adjusted appropriately within a range that allows extraction of the components that exhibit the serotonin synthesis promoting effect contained in the raw chamomile. For example, when the mixed solvent of water and methanol is 100% by volume, the ratio of methanol is 0.1 to 95% by volume.
[0038] When using a mixed solvent of water and ethanol as the extraction solvent, the mixing ratio of water and ethanol may be adjusted appropriately within a range that allows extraction of the GMC contained in the raw chamomile. For example, when the mixed solvent of water and ethanol is 100% by volume, the ratio of ethanol is 0.1 to 95% by volume.
[0039] There are no particular restrictions on the amount of extraction solvent relative to the amount of raw material chamomile, but it is usually about 1 to 100 times the amount of chamomile by weight.
[0040] The method for extracting a solvent extract (extracted liquid) from chamomile may be any method that can extract GMC. A suitable method for producing a chamomile extract is, for example, to bring chamomile into contact with an extraction solvent and stir the mixture for a certain period of time until the active ingredients are sufficiently extracted from the chamomile. The extraction time is appropriately selected taking into consideration the type of extraction solvent, the ratio of chamomile to extraction solvent, etc., but when the extraction solvent is a mixed solvent of water and ethanol, the extraction time may be, for example, 1 to 24 hours.
[0041] The extraction operation in the extraction step is usually carried out at room temperature to avoid deterioration of quality, but can be carried out under heated conditions (for example, at 35°C or higher) to increase extraction efficiency.
[0042] In addition, filtration or centrifugation may be performed to remove residues contained in the extract. The obtained extract may be used as is, or may be subjected to treatments such as dilution, concentration, drying, and purification according to standard methods. If necessary, the extract may be concentrated and dried by methods such as vacuum concentration, freeze drying, and spray drying to remove the solvent, thereby obtaining a solid extract.
[0043] The solid extract may contain an excipient, which further removes moisture from the extract, resulting in a powder composition (dry powder). There are no particular limitations on the excipient, but examples include dextrin, corn starch, lactose, etc. Furthermore, when spray drying, if the extract has a high viscosity, it becomes difficult to spray it. Therefore, by mixing the extract with an excipient and then spray drying it, a powder composition (dry powder) consisting of chamomile extract and excipient can be obtained.
[0044] (2-β-D-glucopyranosyloxy-4-methoxycinnamic acid) 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid (GMC) is a component contained in chamomile extract. By extracting chamomile using an appropriate extraction process, chamomile extract (including fractions) containing GMC as an active ingredient can be obtained.
[0045] GMC is classified into cis and trans isomers depending on the relative arrangement of the carboxyl group and phenyl group bonded to the double bond of the cinnamic acid skeleton, and is a compound represented by the following chemical formula (a) or (b).
[0046] In this specification, GMC (cis isomer) and GMC (trans isomer) are collectively referred to as "GMC", and when distinguishing between them, they are referred to as cis-GMC and trans-GMC, respectively.
[0047] The name of the compound (cis-GMC) represented by the following chemical formula (a) is (Z)-2-glucopyranosyloxy-4-methoxycinnamic acid (English name: cis-2-β-D-glucopyranosyloxy-4-methoxycinnamic acid).
[0048] [ka]
[0049] The name of the compound (trans-GMC) represented by the following chemical formula (b) is (E)-2-glucopyranosyloxy-4-methoxycinnamic acid (English name: trans-2-β-D-glucopyranosyloxy-4-methoxycinnamic acid).
[0050] [ka]
[0051] The above chemical formula (a) (cis-GMC) represents the Z-isomer in which the carboxyl group and phenyl group bonded to the double bond of the cinnamic acid skeleton are both in the cis position relative to each other, and the above chemical formula (b) (trans-GMC) represents the E-isomer in which the carboxyl group and phenyl group bonded to the double bond of the cinnamic acid skeleton are both in the trans position relative to each other.
[0052] The chamomile extract according to the present invention may contain either cis-GMC or trans-GMC, or may contain both. When both are contained, the content of cis-GMC and trans-GMC may be in any ratio as long as the effects of the present invention are achieved.
[0053] The GMC content in the chamomile extract according to the present invention is 25 mg / g or more, 30 mg / g or more, 35 mg / g or more, or 40 mg / g or more. The "content (mg / g) of GMC in chamomile extract" referred to here is a value measured using a liquid chromatograph mass spectrometer, as described in the Examples below.
[0054] As mentioned above, the chamomile extract can be made into a powder composition by incorporating excipients. When preparing a powder composition, the amount of excipient to be added can be set as appropriate within a range that allows further removal of moisture from the chamomile extract and powderization, but it is preferable to add excipients so that the GMC content in the powder composition is 20 mg / g or more, 25 mg / g or more, 30 mg / g or more, or 35 mg / g or more. The "content (mg / g) of GMC in the powder composition" referred to here is a value measured using a liquid chromatograph mass spectrometer, as described in the Examples below.
[0055] <2. Oral composition for mental health> The oral composition for mental health of the present invention (hereinafter simply referred to as "oral composition of the present invention") contains a chamomile extract containing 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid (GMC). Note that since 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid and the chamomile extract are as described above in <1. Composition for promoting serotonin synthesis>, detailed explanations will be omitted.
[0056] The oral composition of the present invention has a mental health effect due to the chamomile extract containing GMC. "Mental health effect" means an effect that is useful for preventing and improving symptoms caused by mental health disorders (stress, depression, insomnia, low mood, etc.).
[0057] In this invention, "mental health" means "a state of well-being in which every individual is able to realize his or her potential, cope with the normal stresses of life, work productively and effectively, and contribute to his or her community," as defined by the World Health Organization (WHO), which is an example of its Japanese translation.
[0058] In the oral composition for mental health of the present invention, "for mental health" means "for the prevention and / or improvement of mental health disorders." Here, "mental health problems" refers to a state in which a subject's mental health is impaired, such as a nervous psychological state, a depressed mood, or a gloomy mood. "Prevention of mental health problems" means preventing the onset of the "mental health problems" and maintaining a healthy state of "mental health." Furthermore, "improvement of mental health problems" refers to the improvement of the "mental health problems" and the return of impaired "mental health" to a normal state. Examples of such improvements include cases where a subject's nervous psychological state, depressed mood, or gloomy mood is alleviated, improved, or resolved, or where the subject is judged to have entered a calm or happy mood.
[0059] In the oral composition of the present invention, the chamomile extract containing GMC may be used as is, or may be used in combination with other ingredients. The other components may be any components that can be safely orally ingested by humans as long as they do not impair the effects of the present invention, and are appropriately determined taking into consideration the form of use (for example, supplements, functional foods, etc., as described below). The blending ratio of the other components can be appropriately selected and determined depending on the purpose as long as they do not impair the effects of the present invention.
[0060] The oral composition of the present invention can be used in any form depending on the purpose, i.e., it can be used as a supplement, functional food, etc.
[0061] When the oral composition of the present invention is used for mental health purposes, the amount of chamomile extract contained therein is appropriately determined within a range that allows the necessary amount to be ingested, taking into consideration the GMC content in the chamomile extract, the type and severity of symptoms associated with mental health disorders, the form of the oral composition of the present invention, and the method of use.
[0062] The subjects for taking the oral composition of the present invention are not particularly limited in terms of gender or age, and include men and women of a wide range of ages. Preferred subjects are women experiencing menopausal symptoms (40 to 64 years old) and women suffering from premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD).
[0063] The intake amount of the oral composition of the present invention is not particularly limited as long as it is an amount that can exert the effects of the present invention, and is appropriately determined depending on the form of the oral composition of the present invention, and the sex, weight, health condition, etc. of the subject to be ingested. The intake amount may be taken in one dose or in divided doses several times a day. In addition, in order to obtain the action or efficacy of the oral composition of the present invention, it is preferable to take the oral composition of the present invention continuously.
[0064] For example, for women with menopausal symptoms (aged 40 to 64), premenstrual syndrome (PMS), or premenstrual dysphoric disorder (PMDD), the daily intake is preferably 8 mg or more, 10 mg or more, 12 mg or more, 15 mg or more, or 20 mg or more in terms of GMC. There is no upper limit to the GMC intake as long as it is safe for humans.
[0065] The following describes suitable forms of the oral composition of the present invention, such as supplements, functional foods, and food additives, but the uses of the oral composition of the present invention are not limited to these.
[0066] The oral composition of the present invention can be mixed with various foods and beverages to form functional foods that can be easily taken orally on a daily basis, and can also be easily taken over a long period of time. The term "functional foods" as used here includes not only general foods but also foods and / or beverages that are taken for the purpose of maintaining or improving health, such as foods for special dietary uses, foods for specified health uses, foods with functional claims, foods with nutrient functions, nutritional supplements, health supplements, and supplements. Among these, foods with functional claims that are health functional foods are the preferred embodiment. Foods with functional claims include foods that claim functionality or effects related to one or more selected from the group consisting of stress, depression, insomnia, low mood, menopausal symptoms, PMS, and prevention and improvement of PMDD.
[0067] The form of the oral composition of the present invention is not particularly limited, and may be any of a tablet, hard capsule, soft capsule, powder, granules, particulate, liquid, rod, plate, block, solid, round, paste, cream, gel, sol, caplet, chewable, stick, jelly, etc.
[0068] When commercializing the oral composition of the present invention, various additives used in foods and beverages, specifically, excipients, coloring agents, preservatives, thickening and stabilizing agents, antioxidants, bleaching agents, antibacterial and antifungal agents, acidulants, seasonings, emulsifiers, strengthening agents, manufacturing agents, fragrances, etc. may be added.
[0069] The foods and beverages that can be used as functional foods are not particularly limited. Examples of foods include bread, candy, drops, jellies, gummies, chewing gum, and other confectioneries, seasonings, and retort pouch foods. Examples of beverages include various types of tea, soft drinks, and nutritional drinks. Examples of tea include packaged beverages filled in PET bottles, cans, jars, etc., instant beverages that can be dissolved in water or hot water, and tea bags.
[0070] The ratio of chamomile extract to be blended into functional foods is arbitrary, but the blending ratio is selected within a range that can contribute to mental health effects.
[0071] The oral composition (chamomile extract) of the present invention can also be used in the form of a supplement. The form of the supplement is not particularly limited and may be any form such as a tablet, powder, powder, granules, capsules (hard capsules, soft capsules), sugar-coated tablets, films, lozenges, jellies, chewable tablets, pastes, gummies, agar tablets, solutions, emulsions, suspensions, etc. The supplement of the present invention may contain any ingredients commonly used in supplements in addition to the oral composition of the present invention. Such ingredients include, for example, amino acids, peptides, vitamins such as vitamin E, vitamin C, vitamin A, vitamin B, and folic acid, minerals, sugars, inorganic salts, citric acid or its salts, tea extract, oils and fats, tonic ingredients such as propolis, royal jelly, and taurine, herbal extracts such as ginger extract and ginseng extract, and herbs such as collagen.
[0072] The ratio of chamomile extract to be mixed into the supplement is arbitrary, but the ratio is selected within a range that can contribute to mental health effects.
[0073] When the oral composition of the present invention is used as a health food, the action or efficacy brought about by the chamomile extract of the present invention may be displayed on the product itself, on the contents such as the product itself, wrapping, container, or packaging, or in advertisements for the product.
[0074] Furthermore, the oral composition (chamomile extract) of the present invention can be used as a food additive either by itself or by adding other ingredients to it. There are no particular restrictions on the other ingredients as long as they can be used as food and beverage additives. The beverages and foods to which the food additive can be added are also arbitrary and not particularly limited.
[0075] The oral composition of the present invention may be mixed with a food additive at any ratio, but the ratio is selected within a range that can contribute to the mental health effects.
[0076] The oral composition of the present invention can also be applied to animals other than humans, and therefore can be used as an oral composition for animals such as pet food. [Example]
[0077] The present invention will be explained in more detail below with reference to examples, but the present invention is not limited to these examples. In addition, the "%" shown in the mixed solvents in the examples indicates "volume %" unless otherwise specified. Furthermore, when the extraction solvent is a mixed solvent, the balance of water is omitted. For example, "50% ethanol" means a mixed solvent of 50% ethanol by volume and 50% water by volume.
[0078] 1. Preparation of chamomile extract Chamomile extracts (1 to 4) were produced by the following method. The chamomile powder (raw chamomile) and extraction solvent used in the production are as follows. Chamomile powder: Powdered Egyptian German chamomile flowers Extraction solvent 1: Water (ultrapure water) Extraction solvent 2: 100% ethanol Extraction solvent 3: 50% ethanol Extraction solvent 4: 30% ethanol
[0079] 20 mL of each of the above extraction solvents (Extraction Solvents 1-4) was added to 1 g of chamomile powder at room temperature. The mixture was vortexed and then subjected to ultrasonic extraction (38 kHz, 200 W) for 40 minutes. The mixture was then centrifuged (3500 rpm, 10 minutes) and the supernatant was collected. Each residue was subjected to a second extraction using 20 mL of each extraction solvent (Extraction Solvents 1-4), and then a third extraction using 15 mL of each extraction solvent (Extraction Solvents 1-4). The three extracts were then mixed and concentrated to dryness, yielding Chamomile Extracts 1-4.
[0080] 2. Evaluation 2-1. Evaluation of serotonin synthesis promoting effect The serotonin synthesis promoting effect of chamomile extract (80% methanol extract) was evaluated by the following procedures (1A) to (3A). The chamomile extract (80% methanol extract) used was obtained by the following manufacturing method. The chamomile powder used was the same as in "1. Manufacturing of chamomile extract."
[0081] (Production of chamomile extract (80% methanol extract)) 150 g of chamomile powder was placed in an Erlenmeyer flask, 2 L of 80% methanol was added, and the mixture was left to stand for 5 days for extraction. The resulting extract was then filtered, and the aqueous filtrate was evaporated using a rotary evaporator to obtain a chamomile extract (80% methanol extract).
[0082] (1A) Cell culture Mouse neuroblastoma Neuro2a cells were precultured in cell growth medium No. 104 (Eagle Medium + NEAA + 10% FBS) in a 10 cm dish until confluent. After washing with phosphate-buffered saline (PBS), the cells were resuspended in medium and plated at 1.0 × 10 cells per well in a 24-well plate. 5 The cells were seeded at a density of 1000 cells / well and cultured overnight in a CO2 incubator (37°C, 5% CO2).
[0083] (2A) Sample addition After overnight incubation, the medium was replaced with cell growth medium No. 104 containing chamomile extract (80% methanol extract) at a concentration of 10 μg / mL, and the cells were incubated in a CO2 incubator for 24 hours. Although not shown, cell viability was measured using an MTT staining solution (5 mg / mL in PBS), and it was confirmed that there was no effect on cell viability in all groups.
[0084] (3A) Comparison of TPH2 gene expression levels by real-time PCR Neuro2a cells were harvested 24 hours after the addition of chamomile extract (80% methanol extract), and total RNA was extracted using the PureLink RNA Mini kit (Invitrogen). cDNA was synthesized from the extracted total RNA using ReverTra Ace qPCR RT Master Mix with gDNA Remover (Toyobo). Real-time PCR was performed using the synthesized cDNA as a template on an AriaMX real-time PCR system (Agilent Technologies). THUNDERBIRD SYBR qPCR Mix (Toyobo) was used for the real-time PCR reaction. The primers for the TPH2 gene were 5'-CTACCCGACTCATGCTTGCC-3' and 5'-CAGGAAGTCTCTTGGGCTCAG-3', and the primers for the internal standard β-actin were 5'-CAAAAGCCACCCCCACTCCTAAGA-3' and 5'-GCCCTGGCTGCCTCAACACCTC-3'. The real-time PCR reaction conditions were initial denaturation at 95°C for 3 minutes, followed by 40 cycles of a two-step PCR reaction consisting of denaturation at 95°C for 3 seconds and annealing / extension at 60°C for 30 seconds. The expression level of the TPH2 gene was evaluated by adding chamomile extract (80% methanol extract).
[0085] The expression level of the TPH2 gene in the control (DMSO) was set to 1, and the relative value of the expression level of the TPH2 gene in chamomile extract 2 was calculated. The results are shown in Figure 1. In Figure 1, a significant difference test was performed on a sample to which DMSO was added instead of chamomile extract (80% methanol extract), and ** indicates p<0.01 (Student's t-test).
[0086] As shown in Figure 1, it was confirmed that an 80% methanol extract of chamomile increased the expression level of the TPH2 gene in Neuro2a cells compared to the control (DMSO).
[0087] 2-2. Evaluation of serotonin synthesis promotion in GMC To investigate the serotonin synthesis promoting effect of 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid (GMC (cis-GMC, trans-GMC)), the serotonin synthesis promoting effect of GMC (cis-GMC, trans-GMC) was evaluated using the same procedures as those described in "2-1. Evaluation of the serotonin synthesis promoting effect of chamomile extract" above (hereinafter referred to as (1B) to (3B)). The samples (cis-GMC, trans-GMC) used for evaluation were the following standard substances. ·cis-GMC:cis-2-beta-D-Glucopyranosyloxy-4-methoxy-cinnamic acid (AnalytiCon Discovery) ·trans-GMC: trans-2-beta-D-Glucopyranosyloxy-4-methoxy-cinnamic acid (AnalytiCon Discovery)
[0088] (1B) Cell culture Mouse neuroblastoma Neuro2a cells were precultured in cell growth medium No. 104 (Eagle Medium + NEAA + 10% FBS) in a 10 cm dish until confluent. After washing with phosphate-buffered saline (PBS), the cells were resuspended in medium and plated at 1.0 × 10 cells per well in a 24-well plate. 5 The cells were seeded at a density of 1000 cells / well and cultured overnight in a CO2 incubator (37°C, 5% CO2).
[0089] (2B) Add sample After overnight incubation, the medium was replaced with cell growth medium No. 104 containing the sample (cis-GMC or trans-GMC) at 100, 200, or 400 μg / mL, and the cells were incubated in a CO 2 incubator for 24 hours. Although not shown, cell viability was measured using an MTT staining solution (5 mg / mL in PBS), and it was confirmed that there was no effect on cell viability in all groups.
[0090] (3B) Comparison of TPH2 gene expression levels by real-time PCR Neuro2a cells were harvested 24 hours after addition of the sample (cis-GMC or trans-GMC), and total RNA was extracted using the PureLink RNA Mini kit (Invitrogen). cDNA was synthesized from the extracted total RNA using ReverTra Ace qPCR RT Master Mix with gDNA Remover (Toyobo). Real-time PCR was performed using the synthesized cDNA as a template on an AriaMX real-time PCR system (Agilent Technologies). THUNDERBIRD SYBR qPCR Mix (Toyobo) was used for the real-time PCR reaction. The primers for the TPH2 gene were 5'-CTACCCGACTCATGCTTGCC-3' and 5'-CAGGAAGTCTCTTGGGCTCAG-3', and the primers for the internal standard β-actin were 5'-CAAAAGCCACCCCCACTCCTAAGA-3' and 5'-GCCCTGGCTGCCTCAACACCTC-3'. The real-time PCR reaction conditions were initial denaturation at 95°C for 3 minutes, followed by 40 cycles of a two-step PCR reaction consisting of denaturation at 95°C for 3 seconds and annealing / extension at 60°C for 30 seconds. The expression level of the TPH2 gene was evaluated by adding cis-GMC and trans-GMC.
[0091] The expression level of the TPH2 gene in the control (DMSO) was set to 1, and the relative values of the expression levels of the TPH2 gene in cis-GMC and trans-GMC were calculated. The results are shown in Figure 2. In Figure 2, a significant difference test was performed on samples to which DMSO was added instead of the sample (cis-GMC or trans-GMC), and ** indicates p<0.01 (Student's t-test).
[0092] As shown in Figure 2, it was confirmed that the expression level of the TPH2 gene in Neuro2a cells was increased with both cis-GMC and trans-GMC compared to the control (DMSO).
[0093] 2-3. Analysis of chamomile extract 2-3-1. Extraction rate of chamomile extract The weights of the chamomile extracts 1 to 4 obtained in the above "1. Production of chamomile extract" were precisely weighed, and the extraction rates (%) were calculated. The extraction rate (%) is calculated using the formula: chamomile extract (g) / chamomile powder (g) x 100. The results are shown in Table 1.
[0094] [Table 1]
[0095] As shown in Table 1, the extractability of chamomile extract was 30% or more for water and aqueous ethanol (50% ethanol, 30% ethanol), confirming a high extractability.
[0096] 2-3-2. GMC content in chamomile extract Chamomile extracts 1 to 4 obtained in "1. Preparation of chamomile extract" above were thoroughly homogenized, and then 10 mg of each chamomile extract (chamomile extracts 1 to 4) was weighed out. 1 mL of 80% methanol was added to 10 mg of each chamomile extract (chamomile extracts 1 to 4), and the mixture was vortexed and then subjected to ultrasonic extraction (38 kHz, 200 W) for 20 minutes. The mixture was then centrifuged at high speed (12,500 rpm, 5 minutes), and the supernatant was collected. The collected supernatant was further diluted with 80% methanol, placed in a vial, and subjected to LC-QTOFMS analysis as follows.
[0097] (LC conditions) Equipment used: Agilent 1290 Infinity 2 Column: Poroshell 120 EC-C18 (2.1 x 100 mm, particle size 2.7 μm) Column temperature: 40℃ Mobile phase: A. Ultrapure water (containing 0.1% formic acid) B. Acetonitrile (containing 0.1% formic acid) Flow rate: 0.2mL / min Gradient conditions: The gradient conditions shown in Table 2 were applied.
[0098] [Table 2]
[0099] (MS conditions) Equipment used: Agilent LC-Q-TOF / MS 6545 Gas Temp: 300℃ Gas Flow: 12L / min Nebulizer: 50 pisg Sheath Gas Temp: 350℃ Sheath Gas Flow: 11L / min Vcap:3500(+);3000(-) Nozzle Voltage: 0V Fragmentor: 130V Skimmer 1: 65V Octopole RF Peak: 750V
[0100] The measurement results of the GMC content in chamomile extracts 1 to 4 are shown in Table 3.
[0101] [Table 3]
[0102] As shown in Table 3, the GMC content in the chamomile extract was 41.6 to 47.7 mg / g.
[0103] 3. Evaluation of mood state (mental health) after oral intake of chamomile extract The effects of oral intake of chamomile extract on mood state (mental health) were evaluated. Specifically, middle-aged and elderly women, including those in the perimenopausal stage, were asked to orally ingest capsules containing a powder composition containing chamomile extract and excipients (hereinafter referred to as "chamomile extract powder") manufactured by the following method every day for 12 weeks, and the effects of oral intake of chamomile extract powder on mood state (mental health) were evaluated.
[0104] (1) Manufacturing method of chamomile extract powder Chamomile extract powder was produced by the following method.
[0105] <Process (1)> A container was charged with 90°C hot water in an amount 20 times the amount of raw chamomile, and the mixture was left to stand for 1 hour to obtain an extract containing the components contained in the raw chamomile. <Process (2)> The obtained extract was concentrated 20 times (actually measured 18 times) by distilling off hot water in a centrifugal thin-film vacuum evaporator (concentrator) to obtain a concentrated liquid. Thereafter, dextrin (NSD300A, manufactured by Sanei Tohka Co., Ltd.) was added to the obtained concentrate so that the concentration was 25% by weight, and the mixture was mixed until uniform. <Process (3)> The resulting mixture was dried using a freeze dryer until the moisture content was 3-7% (actual measurement: 5.3%), and the dried product was pulverized and sieved (mesh opening: 0.4 mm) to obtain chamomile extract powder.
[0106] (2) Preparation of test samples Test capsules were produced using the chamomile extract powder produced in the above "(1) Method for producing chamomile extract powder." The raw materials used to manufacture the test capsules are as follows: Chamomile extract powder (manufactured by SBS Co., Ltd.) Food additive coloring agent (Choco Color 610P, manufactured by Glico Nutrition Foods Co., Ltd.) Starch hydrolysate (Max 1000, manufactured by Matsutani Chemical Industry Co., Ltd.) Calcium stearate (food additive Ca-St, manufactured by Nitto Kasei Kogyo Co., Ltd.) Fine silicon dioxide (Silopage 720, manufactured by Fuji Silysia Chemical Co., Ltd.) HPMC Dark Caramel No. 1 Coating (QUALI-VN Transparent Caramel Color, manufactured by Qualicaps Co., Ltd.)
[0107] Two types of capsules were prepared as test products: capsules of the Example containing chamomile extract powder, and capsules of the Reference Example not containing chamomile extract powder. The blending amounts of the capsules of the Example and Reference Example are shown in Table 4.
[0108] [Table 4]
[0109] (3) Content of GMC in chamomile extract powder and capsules of the example The GMC content in the chamomile extract powder produced by the above "(1) Method for producing chamomile extract powder" and the capsules of the example produced by the above "(2) Preparation of test samples" was quantified by the following method.
[0110] (GMC content in chamomile extract powder) 100 mg of chamomile extract powder was added to 10 mL of 80% aqueous methanol solution and subjected to ultrasonic extraction (38 kHz, 200 W) for 40 minutes. The mixture was then centrifuged (3500 rpm, 10 minutes) and the supernatant was collected. The residue was subjected to a second extraction (ultrasonic extraction (38 kHz, 200 W), 20 minutes) using 8 mL of 80% methanol, and then a third extraction (ultrasonic extraction (38 kHz, 200 W), 20 minutes) using 5 mL of 80% methanol. The three extracts were then combined and adjusted to a constant volume of 25 mL with the extraction solvent, resulting in the respective extracts. Each of the resulting extracts was further centrifuged (18,000 g, 5 min), and the supernatant (4 mg / mL) was then further diluted 100-fold with 80% methanol and subjected to UPLC-UV analysis under the following conditions. The amount of GMC in the chamomile extract powder was found to be 23.09 mg / g (cis-GMC: 15.31 mg / g, trans-GMC: 7.78 mg / g).
[0111] (GMC content in capsules of the example) The capsules (n=3) of the example were each placed in a Falcon tube, and 10 mL of 80% aqueous methanol solution was added. Ultrasonic (38 KHz, 200 W) extraction (40 minutes) was then performed. Then, centrifugation (3000 rpm, 10 min) was performed, and the supernatant was collected. The extraction residue was subjected to a second extraction (ultrasonic (38 KHz, 200 W), 20 min) using 8 mL of 80% methanol, and a third extraction (ultrasonic (38 KHz, 200 W), 20 min) using 5 mL of 80% methanol. The three extractions were then combined and adjusted to a constant volume of 25 mL with the extraction solvent, resulting in the respective extraction solutions. Each of the obtained extracts was further centrifuged (18,000 g, 5 min), and then the supernatant (4 mg / mL) was further diluted 100-fold with 80% methanol and subjected to UPLC-UV analysis under the following conditions. The average amount of GMC in the capsules of this example (n=3) was 2,518.96 μg / capsule (cis-GMC: 1,635.8 μg / capsule, trans-GMC: 883.16 μg / capsule).
[0112] (LC-UV analysis conditions) Equipment used: Agilent 1290 Infinity 2 Column: Poroshell 120 EC-C18 (2.1 x 100 mm, particle size 2.7 μm) Column temperature: 40℃ Mobile phase: A. Ultrapure water (containing 0.1% formic acid) B. Acetonitrile (containing 0.1% formic acid) Flow rate: 0.2mL / min Detection wavelength: 320 nm Gradient conditions: The gradient conditions shown in Table 5 were applied.
[0113] [Table 5]
[0114] (4) Evaluation method Using the capsules of the Examples and Reference Examples manufactured in the above "(2) Preparation of test products," the effects on the mood states of middle-aged and elderly women, including those in the pre- and post-menopausal stages, were evaluated according to the following A to E.
[0115] A. Test Approval This study was approved by the Shiba Palace Clinic Institutional Review Board and conducted in accordance with the Declaration of Helsinki. The protocol was registered with UMIN-CTR (UMIN000055878).
[0116] B. Subject Selection The subjects were women aged 40 to 64 years who had temporary menopausal symptoms, were not receiving treatment for menopausal symptoms, and met all of the following inclusion criteria and did not violate any of the exclusion criteria.
[0117] <Selection criteria> Applicants must meet all of the following criteria: 1) Women aged 40 to 64 at the time of measurement 2) Subjects with temporary menopausal symptoms 3) Persons who have given prior consent via electronic consent
[0118] <Exclusion criteria> If any of the following applies, the application will be excluded. 1) If you are receiving treatment for menopausal symptoms 2) If you are receiving treatment for any illness (including medication) at a medical institution 3) If you have a current or past history of a serious illness 4) Regular use of medicines, supplements, fortified foods, and iron supplements to improve menopausal symptoms If you are taking 5) Those who have a current or past history of drug or food allergies (those who may develop allergic symptoms to the test food) 6) Subjects who have participated in or are currently participating in other clinical trials within one month of obtaining consent or those who plan to participate during the study period 7) People who drink a lot of alcohol on a daily basis (150g or more per week in terms of alcohol) 8) People who smoke 9) Persons working night shifts 10) Those who are judged by the research collaborating physician to be inappropriate for this study
[0119] C. How to Enroll Study Subjects From among the registered survey subjects, the first survey (including a characteristics survey, see Table 7) was administered to subjects who agreed to participate in the first survey, and 320 women aged 40 to 64 who were temporarily experiencing menopausal symptoms were selected. In addition, an online survey on psychological stress responses was administered, and the scores and responses to the characteristics survey were compared against the eligibility and exclusion criteria to screen and select 160 potential subjects. Candidates were then asked to watch a video explaining the study and provide informed consent via electronic consent, and those who agreed to participate were enrolled as study subjects.
[0120] [Table 6]
[0121] D. Method of Allocation The subjects were randomized by stratification, using age and the TMD score of the POMS2 short version assessed at screening as allocation factors, and assigned to either the chamomile group (the group taking the example) or the placebo group (the group taking the reference example) (n=80 per group). Note that the study staff and those involved in this study were unaware of the allocation of each subject, and blinding was maintained.
[0122] E. Test Methods A placebo-controlled, randomized, double-blind, parallel-group comparative study was conducted on subjects. The chamomile group and the placebo group were instructed to take 4 capsules of the Example (1640 mg, GMC content per 4 capsules: 10.08 mg) and 4 capsules of the Reference Example (1240 mg) daily for 12 weeks. The subjects were assessed for mood status using the POMS2 short version (Profile of Mood States 2nd Edition).
[0123] To assess their mood states, subjects were asked to answer 35 questions from the shortened version of the POMS2 at screening and during the intervention period (once per week). The responses were then summed up into seven scales: Tension-Anxiety (TA), Depression-Dejection (DD), Anger-Hostility (AH), Vigor-Activity (VA), Fatigue-Inertia (FI), Confusion-Bewilderment (CB), and Friendliness (F). A total score was also calculated for Total Mood Disturbance (TMD; higher scores indicate more negative mood states, and lower scores indicate more positive mood states).
[0124] (5) Results The results of the mood state survey, based on the scores calculated from the responses of 76 participants in the chamomile group (excluding those who dropped out during the study period), are shown in Figures 3 and 4.
[0125] Furthermore, as shown in Figure 3, the chamomile group showed a gradual decrease in the TMD score (negative mood), which is a measure of overall mood state, over 12 weeks. Also, as shown in Figure 4, the chamomile group showed an increasing trend in the amount of change in VA (vibrancy-vigor; positive mood), a measure of vitality and energy, over 5 to 12 weeks. [Industrial Applicability]
[0126] The composition for promoting serotonin synthesis of the present invention contains a chamomile extract containing 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid as an active ingredient. Furthermore, oral compositions containing the composition for promoting serotonin synthesis of the present invention have excellent effects on mental health disorders and can be suitably used as functional foods, supplements, etc.
Claims
1. A composition for promoting serotonin synthesis, comprising a chamomile extract containing 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid.
2. 2. The composition for promoting serotonin synthesis according to claim 1, wherein the chamomile extract is an extract using one or more solvents selected from water, methanol, and ethanol.
3. A composition for promoting serotonin synthesis, which contains 2-β-D-glucopyranosyloxy-4-methoxycinnamic acid as an active ingredient.
4. An oral composition for mental health, comprising the composition for promoting serotonin synthesis according to any one of claims 1 to 3.
5. The oral composition according to claim 4, which is a functional food or supplement.
Citation Information
Patent Citations
Serotonin secretagogue
JP2017061567A
Serotonin production promoting composition
JP2019156814A
Dietary supplement
JP2020191853A
Antistress agent and relaxation agent
JP2023167322A
